Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 663-668

  Voss, M H ^a   Bastos, D A ^a   Karlo, C A ^a   Ajeti, A ^a   Hakimi, A A ^a   Feldman, D R ^a   Hsieh, J J ^a   Molina, A M ^a   Patil, S ^a   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

MTOR inhibitors; Nonclear cell rCC; Renal cell carcinoma; Sarcomatoid

Indexed keywords

EVEROLIMUS; TEMSIROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; TREATMENT RESPONSE; VERY ELDERLY;

MTOR INHIBITORS; NONCLEAR-CELL RCC; RENAL CELL CARCINOMA; SARCOMATOID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896899516     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt578     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131-133.
3. Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000; 27: 124-137.
4. Lopez-Beltran A, Scarpelli M, Montironi R et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
5. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25: 275-284.
6. Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 65-70.
7. Molina AM, Tickoo SK, Ishill N et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 2011; 34: 454-459.
8. Shuch B, Bratslavsky G, Shih J et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 2012; 109: 1600-1606.
9. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
10. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-209.
11. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
12. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
13. Oudard S, Thiam R, Fournier LS et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 2012; 48: 1512-1518.
14. National Comprehensive Cancer Network (NCCN). Kidney Cancer (version 1. 2013). http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (23 August 2013, date last accessed).
15. Koh Y, Lim HY, Ahn JH et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24: 1026-1031.
16. Blank CU, Bono P, Larkin JMG et al. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGFtargeted therapy: subgroup analysis of REACT. J Clin Oncol 2012; 30 (suppl 5; abstr 402).
17. Golshayan AR, George S, Heng DY et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27: 235-241.
18. Areses MC, Herranz UA, Ferran BB et al. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Med Oncol 2012; 29: 795-798.
19. Voss MH, Hakimi AA, Scott SN et al. Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC). J Clin Oncol 2012; 30 (suppl; abstr 4604).
20. Voss MH, Bastos DA, Karlo C et al. Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: association of long-term responses and oncogenomic events. J Clin Oncol 2013; 31 (suppl 6; abstr 391).